Evidence map›Paper›PMID 35324925›Full record

ArticlePloS one2022

Epitope-based peptide vaccine design and elucidation of novel compounds against 3C like protein of SARS-CoV-2.

Muhammad Sajid, Saigha Marriam, Hamid Mukhtar, Summar Sohail, Muhammad Sajid, Sheikh Arslan Sehgal

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Heliyon · 2023
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Muhammad SajidDepartment of Biotechnology, University of Okara, Okara, Pakistan.
Saigha MarriamDepartment of Microbiology and Molecular Genetics, University of Okara, Okara, Pakistan.
Hamid MukhtarSchool of Law, University of Okara, Okara, Pakistan.
Summar SohailDepartment of Forestry, Kohsar University Murree, Murree, Pakistan.
Muhammad SajidDepartment of Biotechnology, University of Okara, Okara, Pakistan.
Sheikh Arslan SehgalDepartment of Bioinformatics, University of Okara, Okara, Pakistan.ORCID 0000-0002-3901-5344

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronaviruses (CoVs) are positive-stranded RNA viruses with short clubs on their edges. CoVs are pathogenic viruses that infect several animals and plant organisms, as well as humans (lethal respiratory dysfunctions). A noval strain of CoV has been reported and named as SARS-CoV-2. Numerous COVID-19 cases were being reported all over the World. COVID-19 and has a high mortality rate. In the present study, immunoinformatics techniques were utilized to predict the antigenic epitopes against 3C like protein. B-cell epitopes and Cytotoxic T-lymphocyte (CTL) were designed computationally against SARS-CoV-2. Multiple Sequence Alignment (MSA) of seven complete strains (HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, SARS-CoV, MERS-CoV, and SARS-CoV-2) was performed to elucidate the binding domain and interacting residues. MHC-I binding epitopes were evaluated by analyzing the binding affinity of the top-ranked peptides having HLA molecule. By utilizing the docked complexes of CTL epitopes with antigenic sites, the binding relationship and affinity of top-ranked predicted peptides with the MHC-I HLA protein were investigated. The molecular docking analyses were conducted on the ZINC database library and twelve compounds having least binding energy were scrutinized. In conclusion, twelve CTL epitopes (GTDLEGNFY, TVNVLAWLY, GSVGFNIDY, SEDMLNPNY, LSQTGIAV, VLDMCASLK, LTQDHVDIL, TTLNDFNLV, CTSEDMLNP, TTITVNVLA, YNGSPSGVY, and SMQNCVLKL) were identified against SARS-CoV-2.

Indexed as

COVID-19SARS-CoV-2AnimalsEpitopes, T-LymphocyteMolecular Docking SimulationPeptidesSpike Glycoprotein, CoronavirusVaccines, SubunitEpitopes, T-LymphocytePeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, Subunit

Identifiers

PMID35324925
PMCPMC8947391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.